Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials

Delgocitinib cream treatment was well-tolerated and efficacious in maintaining disease control in patients with CHE for up to 52 weeks.

Authors

Institutions

Publication Details

Journal
Journal of the American Academy of Dermatology
Published
2025-03-11
DOI
https://doi.org/10.1016/j.jaad.2025.03.008
Citations
18
Primary Topic
Contact Dermatitis and Allergies
Type
article
Field-Weighted Citation Impact
36.09

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials

Jonathan I. Silverberg, M.N. Crépy, Robert Bissonnette, Luca Stingeni et al.
18 citations
Journal of the American Academy of Dermatology
Contact Dermatitis and Allergies
36.09
article

Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials

Jonathan I. Silverberg, M.N. Crépy, Robert Bissonnette, Luca Stingeni, E. Serra‐Baldrich, Margitta Worm, Ursula Plohberger, Sibylle Schliemann, Tove Agner, Silvia Mariel Ferrucci, Sonja Molin, Marie L. A. Schuttelaar, Marie Louise Oesterdal, Cherry Lou Balita-Crisostomo, Melinda Gooderham, Richard B. Warren
article en
18 citations

Abstract

Delgocitinib cream treatment was well-tolerated and efficacious in maintaining disease control in patients with CHE for up to 52 weeks.

Journal of the American Academy of DermatologyVol. 93(1)
University of Copenhagen (DK), University Medical Center Groningen (NL), University of Groningen (NL), George Washington University (US), Queen's University (CA), University of Perugia (IT), Manchester Academic Health Science Centre (GB), Hospital de Sant Pau (ES), Bispebjerg Hospital (DK), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Manchester University NHS Foundation Trust (GB), ENT and Allergy (US), Clinical Research Center for Hair and Skin Science (DE), Jena University Hospital (DE), Innovaderm (Canada) (CA), NIHR Manchester Biomedical Research Centre (GB), Leo Pharma (Denmark) (DK), Charité - Universitätsmedizin Berlin (DE)
National Institute for Health and Care Research, LEO Pharma, Manchester Biomedical Research Centre
Good health and well-being
Openalex Percentile: Top 0%
Contact Dermatitis and Allergies
36.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.